Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilhan Celik

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 25, 2020
68-months progression-free survival with crizotinib treatment in a patient with metastatic ALK positive lung adenocarcinoma and sarcoidosis: A case reportOzgur Tanriverdi, Mehmet L Tarimer, Ceren D Pak, et al.
Langenbeck'S Archives of Surgery|February 8, 2006
Evaluation of the McPeek postoperative outcome score in three trialsArtur Bauhofer, Wilfried Lorenz, Michael Koller, et al.
Iranian Red Crescent Medical Journal|May 30, 2015
Evaluation of the protective effect of silibinin against diazinon induced hepatotoxicity and free-radical damage in rat liverHalil Beydilli, Nigar Yilmaz, Esin Sakalli Cetin, et al.
Clinical Colorectal Cancer|August 28, 2013
Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assayShao-Chun Chang, Jonathan Denne, Luping Zhao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 26, 2014
Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancerJean-Yves Douillard, Robert Pirker, Kenneth J O'Byrne, et al.
Blood|September 24, 2004
Angiostatin is a novel anti-inflammatory factor by inhibiting leukocyte recruitmentTriantafyllos Chavakis, Athanasios Athanasopoulos, Joong-Sup Rhee, et al.
European Journal of Cancer (Oxford, England : 1990)|December 26, 2012
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studiesLisa Licitra, Stephan Störkel, Keith M Kerr, et al.
Surgery|March 27, 2007
Perioperative prophylaxis with granulocyte colony-stimulating factor (G-CSF) in high-risk colorectal cancer patients for an improved recovery: A randomized, controlled trialArtur Bauhofer, Ulrike Plaul, Alexander Torossian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2011
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation statusEric Van Cutsem, Claus-Henning Köhne, István Láng, et al.
International Journal of Colorectal Disease|June 7, 2005
TNP-470 fails to block the onset of angiogenesis and early tumor establishment in an intravital minimal disease modelGrigore Cernaianu, Sibylle Frank, Katrin Erbstösser, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 25, 2020
68-months progression-free survival with crizotinib treatment in a patient with metastatic ALK positive lung adenocarcinoma and sarcoidosis: A case reportOzgur Tanriverdi, Mehmet L Tarimer, Ceren D Pak, et al.
Langenbeck'S Archives of Surgery|February 8, 2006
Evaluation of the McPeek postoperative outcome score in three trialsArtur Bauhofer, Wilfried Lorenz, Michael Koller, et al.
Iranian Red Crescent Medical Journal|May 30, 2015
Evaluation of the protective effect of silibinin against diazinon induced hepatotoxicity and free-radical damage in rat liverHalil Beydilli, Nigar Yilmaz, Esin Sakalli Cetin, et al.
Clinical Colorectal Cancer|August 28, 2013
Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assayShao-Chun Chang, Jonathan Denne, Luping Zhao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 26, 2014
Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancerJean-Yves Douillard, Robert Pirker, Kenneth J O'Byrne, et al.
Blood|September 24, 2004
Angiostatin is a novel anti-inflammatory factor by inhibiting leukocyte recruitmentTriantafyllos Chavakis, Athanasios Athanasopoulos, Joong-Sup Rhee, et al.
European Journal of Cancer (Oxford, England : 1990)|December 26, 2012
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studiesLisa Licitra, Stephan Störkel, Keith M Kerr, et al.
Surgery|March 27, 2007
Perioperative prophylaxis with granulocyte colony-stimulating factor (G-CSF) in high-risk colorectal cancer patients for an improved recovery: A randomized, controlled trialArtur Bauhofer, Ulrike Plaul, Alexander Torossian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2011
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation statusEric Van Cutsem, Claus-Henning Köhne, István Láng, et al.
International Journal of Colorectal Disease|June 7, 2005
TNP-470 fails to block the onset of angiogenesis and early tumor establishment in an intravital minimal disease modelGrigore Cernaianu, Sibylle Frank, Katrin Erbstösser, et al.
Pageof 5